A woman with atypical hemolytic uremic syndrome (aHUS) successfully underwent a second kidney transplant as treatment with Soliris (eculizumab) largely prevented or eased the complications that led to failure of her first transplant. The medication has helped stabilize the woman’s kidney function for four years, researchers wrote in a…
News
A COVID-19 infection apparently triggered the development of atypical hemolytic uremic syndrome (aHUS) in a 75-year-old man who had recently received a kidney transplant, according to a case report. Treatment with Ultomiris (ravulizumab) helped resolve his symptoms, supporting the use of the medication post-kidney transplant. Some kidney transplant…
Recurrent pancreatitis, or inflammation of the pancreas, an organ essential for digestion, may trigger atypical hemolytic uremic syndrome (aHUS) in people with mutations that increase the risk of this immune system-related condition. That’s according to a new report detailing the case of a young boy in India who was…
A man who developed a severe, full-body flare of psoriasis that caused his skin to peel and swell and triggered kidney failure and atypical hemolytic uremic syndrome (aHUS) improved after being treated with corticosteroids, intravenous immunoglobulin, and the complement inhibitor Soliris (eculizumab). “Early recognition of this overlap syndrome…
A previously healthy young man in Greece who later developed atypical hemolytic uremic syndrome (aHUS) improved rapidly after being treated with the complement inhibitor Soliris (eculizumab), which helped his heart function recover over time, but delayed therapy was linked to permanent kidney failure requiring dialysis. “This case emphasizes…
Complement inhibitors and plasma exchange therapy are equally safe and effective for atypical hemolytic uremic syndrome (aHUS), but complement inhibitors like Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) offer an edge in preventing relapses, especially in children, according to a new pooled analysis of real-world data. The analysis reveals…
A 4-year-old boy developed post-infectious glomerulonephritis (PIGN) and later atypical hemolytic uremic syndrome (aHUS), both of which affect the kidneys, but once doctors started treatment with the complement inhibitor Soliris (eculizumab), his blood problems resolved, his kidney function recovered, and he achieved long-term remission. “This case shows that…
A rare case of atypical hemolytic uremic syndrome (aHUS) developed after a kidney transplant in a young man and was successfully treated with Soliris (eculizumab), according to a case study. “The occurrence of [aHUS] following [kidney] transplantation is extremely uncommon and associated with adverse outcomes, often resulting in…
A teenage boy who was diagnosed in childhood with atypical hemolytic uremic syndrome (aHUS) was later found to also have Fabry disease and an inherited heart condition called hypertrophic cardiomyopathy — what researchers described as an “unusual trilogy” of rare diseases. The two additional genetic conditions were identified…
Treatment with Soliris (eculizumab), along with several immune-suppressing medications, was part of a treatment strategy that supported a woman with atypical hemolytic uremic syndrome (aHUS) in receiving a kidney donated from her mother — even though testing showed the two were not fully immunologically compatible. The case was…
Recent Posts
- Soliris enables successful second kidney transplant: Case study
- The struggles of losing weight when you’re chronically ill
- COVID-19 triggers aHUS in man following kidney transplant
- Heart complications were a puzzling part of my aHUS journey
- Inflammation of the pancreas may trigger aHUS, boy’s case shows
- Patients need more help to pay for rare disease treatment
- Man’s psoriasis triggers kidney failure, aHUS in rare overlap
- How inflammation from multiple conditions led to an eye emergency
- Early treatment critical in aHUS to prevent lasting kidney damage
- I struggle daily with deconditioning from my multiple illnesses